Optimizing Management of X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) with Novel Targeted Therapies

Released On
October 18, 2021

Expires On
October 18, 2022

Media Type

Completion Time
60 minutes

Dentistry, Endocrinology, Genetics, Nephrology, Nutrition, Pain Management, Pathology, Pediatrics, Physiatry, Primary Care, Radiology, Surgery

Bone Disorders, Neonatal, Pain, Pediatrics, Radiology, Rickets

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Excel Continuing Education.

This activity is supported in part by an independent education grant from Ultragenyx.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses; 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This CME activity is designed to meet the educational needs of pediatric and adult endocrinologists, pediatricians, and other HCPs who may contribute to the multidisciplinary team, such as radiologists, pathologists, nurse practitioners, and physician assistants interested in increasing their knowledge regarding XLH and TIO, as well as to improve competence in diagnosing and treating these diseases.

Program Overview

This CME-accredited on-demand webinar was presented live as an independent satellite symposium at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting in early October. Dr. Signe Beck-Nielsen, a key opinion leader and specialist in hypophosphatemic rickets from Aarhus University Hospital in Denmark, covers the diagnosis and clinical presentation of XLH including best practices for management. Dr. Thomas Weber, an expert in tumor-induced osteomalacia from Duke University, addresses the diagnosis of TIO including surgical/non-surgical management and novel therapies for treatment that have the potential to improve patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the pathophysiological basis for symptom development in XLH and TIO
  • Identify clinical manifestations and diagnostic methods to make a timelier diagnosis of XLH and TIO
  • Assess recent developments in the treatment of these two FGF-23 linked disorders
  • Effectively integrate new evidence-based therapeutic strategies into clinical practice when managing patients with XLH and TIO




Signe Beck-Nielsen, MD, PhD (XLH)

Consultant at the Center for Rare Diseases, Skejby
Aarhus University Hospital
Aarhus, Denmark


Thomas J. Weber, MD (TIO)

Professor of Medicine
Department of Medicine
Division of Endocrinology, Metabolism, and Nutrition
Duke University School of Medicine
Durham, NC


Accreditation Statement

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

EXCEL Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NOTE: AAPA and the ANCC both accept credits from activities that have been approved by an ACCME accredited provider.

NOTE: The UEMS-EACCME® = European Union of Medical Specialists and European Accreditation Council for CME have mutual recognition agreements with the American Medical Association for live events and e-learning materials. European physicians can earn their ECMEC®s (European CME credits) by either attending a live presentation approved by an ACCME accredited provider such as EXCEL, or participating in e-learning activities (on-demand webcasts) from accredited providers from the USA that have been certified for AMA PRA Category 1 Credits™.

Nursing Accreditation Statement

EXCEL is accredited by the Florida Board of Nursing, provider # 50-619, and designates this activity for 1 contact hour.

Disclosures of Conflicts of Interest

Signe Beck-Nielsen, MD, PhD

  • Speaker, Consultant, Contracted Research: Kyowa Kirin
  • Consultant: Inozyme Pharma


Thomas J. Weber, MD

  • Primary Investigator, Consultant: Ultragenyx Pharma
  • Adjudication committee member for Duke Clinical Research Inst. on Endocrine Events: Sanofi
  • Editorial Support: Elsevier
  • ESAP Peer Review Committee: Endocrine Society (not an ineligible company)
  • Metabolic Drug Advisory Committee: FDA (not an ineligible company)


The EXCEL staff and Peer Reviewer have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

EXCEL CONTINUING EDUCATION requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: info@excelcme.com